第一医药(600833) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥475,709,108.90, representing an increase of 8.72% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥17,535,794.07, a significant increase of 50.25% year-on-year[2]. - The basic earnings per share for Q3 2024 was ¥0.0786, reflecting a growth of 50% compared to the same period last year[3]. - Total operating revenue for the first three quarters of 2024 reached ¥1,368,880,300.43, a slight increase of 2.9% compared to ¥1,335,807,678.27 in the same period of 2023[15]. - Net profit for the first three quarters of 2024 was ¥147,358,092.70, representing a significant increase of 156.5% compared to ¥57,500,776.14 in the previous year[16]. - Operating profit surged to ¥153,647,524.75, compared to ¥47,887,098.54 in the same period last year, marking an increase of 220.5%[16]. - Earnings per share (EPS) for the third quarter of 2024 was ¥0.6604, up from ¥0.2578 in the same quarter of 2023, reflecting a growth of 156.5%[17]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,928,997,582.33, an increase of 3.53% from the end of the previous year[3]. - As of September 30, 2024, the total assets of Shanghai First Pharmaceutical Co., Ltd. amounted to RMB 1,928,997,582.33, an increase from RMB 1,863,168,849.07 at the end of 2023, representing a growth of approximately 3.4%[11]. - The company's current assets totaled RMB 1,095,083,414.64, a decrease of about 2.0% from RMB 1,117,232,878.38 at the end of 2023[11]. - The total liabilities decreased to RMB 800,299,902.38 from RMB 854,715,417.70, showing a reduction of approximately 6.4%[13]. - The equity attributable to shareholders rose to RMB 1,120,187,196.69, up from RMB 1,001,446,115.48, marking an increase of around 11.9%[14]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥51,595,472.56, showing a decline of 120.98% compared to the same period last year[3]. - Cash inflow from operating activities totaled ¥1,497,797,001.50, down 8.6% from ¥1,639,488,193.78 in the previous year[18]. - The net cash flow from operating activities was -51,595,472.56, a significant decrease compared to 245,917,000.02 in the previous year[19]. - The total cash outflow from investing activities was 356,197,338.89, compared to 381,073,182.87 in the same period last year[19]. - The net cash flow from investing activities was 4,793,074.33, a recovery from -174,781,281.30 in the previous year[19]. - The net cash flow from financing activities was -72,956,521.72, an improvement from -409,148,534.55 in the same period last year[19]. - The ending balance of cash and cash equivalents was 277,907,854.36, up from 167,069,914.29 year-over-year[20]. - The cash and cash equivalents net decrease was -121,820,138.11, compared to -337,562,827.99 in the previous year[19]. Operational Costs and Expenses - Total operating costs increased to ¥1,367,296,395.88, up 4.6% from ¥1,307,287,990.97 year-over-year[15]. - Sales expenses increased to ¥191,832,654.92, up 13.5% from ¥169,173,315.96 year-over-year[15]. - Tax expenses rose to ¥4,125,527.36, compared to ¥3,919,891.47 in the same period last year, an increase of 5.3%[15]. - Financial expenses showed a net income of -¥10,688,942.32, worsening from -¥5,599,106.84 in the previous year[15]. - Other income for the first three quarters of 2024 was ¥415,914.24, a decrease from ¥3,037,954.43 in the same period of 2023[16]. Non-Recurring Gains and Losses - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥579,383.74, down 79.08% year-on-year[2]. - Non-recurring gains and losses for the current period totaled ¥16,956,410.33, with significant contributions from asset disposals and other income[4]. - The company reported a decrease in net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date, primarily due to increased operational costs and intensified industry competition[6].